Havn Life announces DTC Eligibility of Its Common Shares in the United States

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce today that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States. The Company’s common shares are quoted in the United States on the OTC Venture Market under the symbol “HAVLF”

DTC is a subsidiary of the Depository Trust & Clearing Corporation, a United States company that manages the electronic clearing and settlement of publicly-traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered “DTC eligible.” This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

In addition to trading in the United States on the OTC Venture Market, the Company’s common shares will continue to trade on the Canadian Securities Exchange (CSE) under the symbol “HAVN” and the Frankfurt Stock Exchange under the symbol “5NP.”

“Executing on our milestone of obtaining DTC eligibility demonstrates Havn Lifes’ commitment to increased visibility and accessibility for shareholders moving into 2021,” said Chief Executive Officer, Tim Moore. “We believe this DTC eligibility will expand our exposure to a larger portion of the investment community, while providing a lower-cost and more seamless trading process that gives investors the ability to transfer shares between U.S. brokerage accounts.”

On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer


About Havn Life Sciences Inc.

Havn Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram and Youtube.

Connect

Investor Relations
[email protected]
(604) 687-7130

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life
Youtube: @HavnLife

Media Contact
[email protected]
(647) 896-8078

The post Havn Life announces DTC Eligibility of Its Common Shares in the United States appeared first on HAVN Life.

Learn more about the psychedelics industry at Microdose.

Get Bi-Weekly Updates

Subscribe to the Market Insights Report

Each Wednesday and Saturday, we will send you a review of the latest price movements, financial analysis, and original insights on the emerging financial landscape of the psychedelic industry.

  • This field is for validation purposes and should be left unchanged.
Havn Life

Havn Life

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds.